Ionis Pharmaceuticals, Inc. Common Stock (IONS) Stock Price

IONSStock

$63.57+45.33%52W

Market Cap$10.56B

P/E—

PEG Ratio27.33

Div yield—

Beta0.33

IONS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-35.79%

Price vs S&P 500 (4W)9.14%

PEG Ratio27.33

VGM Score36.81

Book Value / Share (Quarterly)$2.65

P/TBV (Annual)5.79x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)17.12%

Cash Flow / Share (Quarterly)$-3.39

Price vs S&P 500 (YTD)-33.54%

Gross Margin (TTM)98.17%

Net Profit Margin (TTM)-64.66%

EPS (TTM)$-3.47

10-Day Avg Trading Volume2.24M

EPS Excl Extra (TTM)$-3.47

Revenue Growth (5Y)5.29%

EPS (Annual)$-2.38

ROI (Annual)-13.53%

Gross Margin (Annual)98.31%

Net Profit Margin (5Y Avg)-40.14%

Cash / Share (Quarterly)$12.40

Revenue Growth QoQ (YoY)-40.73%

ROA (Last FY)-10.82%

Revenue Growth TTM (YoY)-7.51%

EBITD / Share (TTM)$-3.57

ROE (5Y Avg)-60.13%

Operating Margin (TTM)-68.00%

Cash Flow / Share (Annual)$-1.96

P/B Ratio21.10x

P/B Ratio (Quarterly)29.80x

Net Income / Employee (Annual)$-272,000

EV / Revenue (TTM)12.40x

Net Interest Coverage (TTM)-4.22x

ROA (TTM)-17.39%

EV / EBITDA (TTM)323.58x

EPS Incl Extra (Annual)$-2.38

Current Ratio (Annual)3.83x

Quick Ratio (Quarterly)7.73x

3-Month Avg Trading Volume2.59M

52-Week Price Return45.33%

Revenue / Employee (TTM)$623,500

Tangible BV / Share (Quarterly)$3.98

P/S Ratio (Annual)9.83x

Asset Turnover (Annual)0.27x

52-Week High$86.74

Operating Margin (5Y Avg)-45.13%

EPS Excl Extra (Annual)$-2.38

CapEx CAGR (5Y)7.95%

Tangible BV CAGR (5Y)56.47%

26-Week Price Return-24.54%

Quick Ratio (Annual)3.81x

13-Week Price Return-18.13%

Total Debt / Equity (Annual)4.77x

Current Ratio (Quarterly)7.89x

Enterprise Value$10.84B

Revenue / Share Growth (5Y)2.46%

Asset Turnover (TTM)0.27x

Book Value / Share Growth (5Y)-10.77%

Revenue / Employee (Annual)$673,100

Inventory Turnover (Annual)1.41x

Pretax Margin (Annual)-40.22%

Cash / Share (Annual)$16.40

3-Month Return Std Dev60.04%

Gross Margin (5Y Avg)98.36%

Net Income / Employee (TTM)$-403,100

ROE (Last FY)-77.98%

Net Interest Coverage (Annual)-8.39x

EPS Basic Excl Extra (Annual)$-2.38

P/FCF (TTM)16.88x

Receivables Turnover (TTM)15.69x

Total Debt / Equity (Quarterly)4.35x

EPS Incl Extra (TTM)$-3.47

Receivables Turnover (Annual)11.93x

ROI (TTM)-21.75%

P/S Ratio (TTM)10.61x

Pretax Margin (5Y Avg)-39.07%

Revenue / Share (Annual)$5.90

Tangible BV / Share (Annual)$5.26

Price vs S&P 500 (52W)27.02%

Year-to-Date Return-21.58%

5-Day Price Return4.06%

EPS Normalized (Annual)$-2.38

ROA (5Y Avg)-9.98%

Net Profit Margin (Annual)-40.41%

Month-to-Date Return19.84%

Cash Flow / Share (TTM)$-2.77

EBITD / Share (Annual)$-2.32

Operating Margin (Annual)-40.45%

LT Debt / Equity (Annual)3.88x

ROI (5Y Avg)-13.25%

LT Debt / Equity (Quarterly)4.35x

EPS Basic Excl Extra (TTM)$-3.47

P/TBV (Quarterly)11.12x

P/B Ratio (Annual)26.20x

Inventory Turnover (TTM)0.54x

Pretax Margin (TTM)-64.30%

Book Value / Share (Annual)$2.99

Price vs S&P 500 (13W)-20.93%

Beta0.33x

P/FCF (Annual)493.43x

Revenue / Share (TTM)$5.28

ROE (TTM)-110.92%

52-Week Low$41.71

vGradeD

gGradeD

mGradeC

vgmGradeD

IONS Earnings Surprise History

Q2 250.85est. 0.16

Q3 25-0.61est. -1.05

Q4 25-1.15est. -1.22

Q1 26-0.30est. -0.78

Q2 26-0.42est. -0.88

IONS Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.10

4.12

4.15

4.06

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$67.01

About Ionis Pharmaceuticals, Inc. Common Stock

Ionis Pharmaceuticals is a leader in antisense technology with a diverse clinical pipeline targeting cardiovascular, metabolic, neurological, and rare diseases. The company has established multiple marketed drugs through partnerships, including Spinraza (spinal muscular atrophy), Qalsody (ALS), and Tegsedi (ATTR amyloidosis), while achieving its first independent launches in 2025 with Tryngolza and Dawnzera. Ionis combines partnership-driven revenue streams with growing direct commercialization capabilities.